OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD
Sponsor: Opthea Limited
Terminated
The primary endpoint was not achieved in the study.
Other terminated trials from Opthea Limited
More terminations from Opthea Limited
Other Neovascular Age-related Macular Degeneration trials with similar outcome
- NCT04757610 · Phase PHASE3 · Mar 2025
- NCT03577899 · Phase PHASE3 · May 2021
- NCT03630952 · Phase PHASE3 · May 2021
Browse all Neovascular Age-related Macular Degeneration trials
Listed as NCT04757636, this PHASE3 trial focuses on Neovascular Age-related Macular Degeneration and remains terminated or withdrawn. Sponsored by Opthea Limited, it has been updated 21 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
21 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE3
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 16 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — Apr 2024 [monthly]
Recruiting PHASE3
-
Sep 2022 — Dec 2023 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Opthea Limited
For direct contact, visit the study record on ClinicalTrials.gov .